DPP-4 Inhibitors: Available Agents
The commercially available DPP-4 inhibitors include sitagliptin, saxagliptin, vildagliptin, linagliptin, and alogliptin 1.
Complete List of DPP-4 Inhibitors
The following agents are FDA-approved and/or commercially available DPP-4 inhibitors for type 2 diabetes management:
- Sitagliptin - First-in-class agent, approved 2006
- Saxagliptin - Approved 2009
- Vildagliptin - Available in EU and many countries (not FDA-approved in US)
- Linagliptin - Approved 2011
- Alogliptin - Approved 2010 (initially only in Japan, now more widely available)
Mechanism of Action
These oral medications work by inhibiting the DPP-4 enzyme, which normally degrades incretin hormones (GLP-1 and GIP). By preventing this degradation, DPP-4 inhibitors increase endogenous incretin levels, leading to glucose-dependent enhancement of insulin secretion and suppression of glucagon secretion 1.
Key Clinical Characteristics
Efficacy: DPP-4 inhibitors reduce HbA1c by 0.4% to 0.9% 1
Hypoglycemia risk: Minimal when used as monotherapy; low risk profile 1, 2
Weight effect: Weight-neutral 2
Cardiovascular safety: Sitagliptin, saxagliptin, and alogliptin have demonstrated cardiovascular safety in outcome trials, though saxagliptin and alogliptin showed increased heart failure hospitalization risk 3, 2, 3
Important Prescribing Considerations
Renal dosing adjustments required for: Sitagliptin, saxagliptin, alogliptin, and vildagliptin 1
No renal dose adjustment needed: Linagliptin - can be used without modification in hepatic or renal insufficiency 1
Avoid concurrent use: DPP-4 inhibitors should not be combined with GLP-1 receptor agonists due to lack of additional glucose-lowering benefit 4